APP and Alzheimer disease: Additionally, sphingosine-1-phosphate metabolism was identified as a key pathway involved in AD progression, so authors performed APP/PS1 mice tests with fingolimod (an S1P receptor modulator) to evaluate the efficiency of the discovered target modulation in AD treatment.